Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-13

FDA Approved: BYLVAY — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BYLVAY (odevixibat) submitted by Ipsen Biopharmaceuticals, Inc. The action updates the labeling to reflect new i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BYLVAY (odevixibat)

Snippet

SUPPL AP for BYLVAY (ODEVIXIBAT)